Drug Profile
BAY 2328065
Alternative Names: BAY2328065Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Bayer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Endometriosis
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Endometriosis(In volunteers) in Germany (PO, Liquid)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Endometriosis(In volunteers) in Germany (PO, Tablet)
- 20 Jan 2022 BAY 2328065 is still in phase I trials for Endometriosis (In volunteers) in Germany (PO) (Evotec pipeline, January 2022)